不同剂量噻托溴铵吸入治疗慢性阻塞性肺疾病的临床疗效

发布时间：2018-02-26 06:28

本文关键词： 慢性阻塞性肺疾病噻托溴铵临床观察　出处：《中国生化药物杂志》2014年02期 　论文类型：期刊论文

【摘要】：目的观察稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者予以不同剂量噻托溴铵吸入剂的临床疗效。方法 134例吸烟稳定期COPD患者按入院先后交替分入常规治疗组(n=46),男40人,女6人,年龄(61.7±9.3)岁;18μg噻托溴铵观察组(n=45),男40人,女5人,年龄(63.4±8.5)岁;32μg噻托溴铵观察组(n=43),男39人,女4人,年龄(63.2±9.0)岁,3组予以相同常规治疗,18μg噻托溴铵观察组给予18μg/日噻托溴铵,32μg噻托溴铵观察组给予32μg/日噻托溴铵。治疗持续12w,在治疗开始后1d、1w、4w、8w、12w等不同观察时间点观测肺功能及呼吸困难的改善程度。结果治疗后,3组患者的肺功能及呼吸困难较治疗前均具有一定程度的改善。但与常规治疗组较,2观察组治疗后的圣乔治呼吸功能调查问卷(St.George's Respiratory Questionnaire,SGRQ)与过度呼吸困难指数(transition dyspnea index,TDI)评分显著优于对照组(P0.05),第一秒用力呼气量(forced expiratory volume in one second,FEV1)较治疗前显著改善(P0.05),32μg噻托溴铵观察组改善更为明显,与18μg噻托溴铵观察组差异显著(P0.05)。结论噻托溴铵能够通过扩张支气管、缓解呼吸困难,有效地改善COPD患者的症状。且服用剂量为32μg/d时,疗效优于18μg/d。
[Abstract]:Objective to observe the clinical efficacy of different doses of tiotropium bromide inhalation in patients with chronic obstructive pulmonary disease (pulmonary) in stable stage. Methods 134 patients with stable smoking COPD were randomly divided into routine treatment group (40 males and 6 females). The age was 61.7 卤9.3) years old, 18 渭 g tiotropium bromide observation group (40 males, 5 females, 63.4 卤8.5) years old, 32 渭 g tiotropium bromide observation group (39 males, 4 females). The three groups were given the same routine treatment with 18 渭 g tiotropium bromide and 32 渭 g tiotropium bromide per day for 12 weeks. The lung was observed at different time points, such as 1 day, 1 week, 4 weeks and 8 weeks after treatment. Results the pulmonary function and dyspnea of the three groups after treatment were improved to a certain extent, but compared with the routine treatment group, the respiratory function of the observation group after treatment was improved to some extent. The scores of St. George s Respiratory questionnaire and transition dyspnea index were significantly better than those of the control group (P 0.05), and the forced expiratory volume in one second time FEV1 at 1 second was significantly better than that in the control group before treatment, and the improvement was more obvious in the observation group with 32 渭 g tiotropium bromide before treatment. Conclusion tiotropium bromide can relieve dyspnea and improve the symptoms of COPD patients by dilating the bronchus, and the therapeutic effect is better than 18 渭 g / d at the dose of 32 渭 g / d.
【作者单位】：重庆市丰都县人民医院呼吸内科;重庆医科大学附属第一医院呼吸内科;
【基金】：国家临床重点专科专项经费资助(2012949)
【分类号】：R563.9

【参考文献】